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Objective: Obesity-associated impaired fat accumulation in the visceral adipose tissue can lead to ectopic fat
deposition and increased risk of insulin resistance and type 2 diabetes mellitus (T2DM). This study investigated
whether impaired adipogenesis of omental (OM) adipose tissues and elevated 4-hydroxynonenal (4-HNE)
accumulation contribute to this process, and if combined metformin and insulin treatment in T2DM patients
could rescue this phenotype.
Methods: OM adipose tissues were obtained from forty clinically well characterized obese individuals during
weight reduction surgery. Levels of 4-HNE protein adducts, adipocyte size and number of macrophages were
determined within these tissues by immunohistochemistry. Adipogenic capacity and gene expression proﬁles
were assessed in preadipocytes derived from these tissues in relation to insulin resistance and in response to 4-
HNE, metformin or combined metformin and insulin treatment.
Results: Preadipocytes isolated from insulin resistant (IR) and T2DM individuals exhibited lower adipogenesis,
marked by upregulation of anti-adipogenic genes, compared to preadipocytes derived from insulin sensitive (IS)
individuals. Impaired adipogenesis was also associated with increased 4-HNE levels, smaller adipocytes and
greater macrophage presence in the adipose tissues. Within the T2DM group, preadipocytes from combined
metformin and insulin treated subset showed better in vitro adipogenesis compared to metformin alone, which
was associated with less presence of macrophages and 4-HNE in the adipose tissues. Treatment of
preadipocytes in vitro with 4-HNE reduced their adipogenesis and increased proliferation, even in the presence
of metformin, which was partially rescued by the presence of insulin.
Conclusion: This study reveals involvement of 4-HNE in the impaired OM adipogenesis-associated with insulin
resistance and T2DM and provides a proof of concept that this impairment can be reversed by the synergistic
action of insulin and metformin. Further studies are needed to evaluate involvement of 4-HNE in metabolically
impaired abdominal adipogenesis and to conﬁrm beneﬁts of combined metformin-insulin therapy in T2DM
patients.
1. Introduction
Obesity increases the risk of insulin resistance and type 2 diabetes
mellitus (T2DM) [1]. However, some obese individuals, often referred
to as the insulin sensitive (IS) or metabolically healthy obese (MHO),
exhibit a lower risk of these diseases than predicted by their obesity [2].
Understanding the mechanisms underlying the protection found in IS
obesity could help individuals suﬀering from pathological obesity.
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Obesity is characterized by increased size of adipose tissue through
hypertrophy and hyperplasia of adipocytes [3]. Preadipocytes, an
abundant cell population within the adipose tissue, replenish the
adipocyte pool through adipogenesis [4]. Superior adipogenesis of
preadipocytes isolated from sub-cutaneous (SC) adipose tissues taken
from IS obese individuals compared to insulin resistant (IR) counter-
parts was recently suggested to play a role in the protection process of
IS obesity, which is partially mediated by lower IL-6 secretion and
oxidative stress [5,6]. Obesity-associated oxidative stress leads to
elevated reactive oxygen species (ROS) production causing lipid
peroxidation within the adipose tissue [7] and accumulation of reactive
aldehydes [8,9]. Elevated 4-hydroxynonenal (4-HNE), a bioactive lipid
peroxidation product, leads to progressive impairment of cell structure
and function via formation of stable 4-hydroxyalkenals with proteins,
phospholipids and DNA [10,11]. Elevation of 4-HNE has been
associated with impaired adipogenesis, insulin resistance, atherosclero-
sis and even obesity of apparently healthy people [6,12–15].
Metformin (dimethylbiguanidine), the most widely used drug for
the treatment of T2DM [16,17], is an insulin-sensitizing agent that
provides glycemic control, especially in obese individuals [18].
Metformin can reduce adipose tissue size in vivo [19] and in vitro by
inhibiting adipogenesis, decreasing lipogenic gene expression and
increasing AMPK activity and glucose intake [20–22]. Metformin is
frequently given to T2DM in combination with insulin [23]. Previous
studies have shown that intensive insulin therapy reverses the decrease
in adipocyte glucose transport activity in T2DM [24] and counters
inﬂammation by decreasing levels of IL-6 and TNFα [25]. Insulin is
commonly used in in vitro studies to induce adipogenesis, as it triggers
a series of transcription factors that drive diﬀerentiation of pre-
adipocytes into mature adipocytes including phosphorylation and
activation of CREB [26] and PI 3-kinase [27].
Characterization of adipogenesis in the omental (OM) adipose
tissues, a depot that is associated with increased metabolic disease
risk [28], in IS, IR and T2DM obese individuals remains to be
elucidated. Additionally, the eﬀects of metformin on human OM
adipogenesis has not been tested, although metformin-mediated
glucose uptake by SC and OM adipocytes was previously described
[29]. Comparing adipogenesis of OM-derived preadipocytes between IS
and IR individuals and the impact of local 4-HNE on this process in
primary cultures would provide valuable insights into the potentially
protective mechanism associated with the IS group. The aims of the
study were to test three hypotheses: 1) adipogenic capacity of OM
preadipocyte is impaired in IR and T2DM individuals compared to IS
subjects, 2) this impairment is accompanied by elevated 4-HNE
accumulation in the adipose tissue that can directly inhibit adipogen-
esis, and 3) a combination of metformin/insulin treatment can rescue
impaired OM adipogenesis.
2. Materials and methods
2.1. Materials
IL-6 and leptin ELISAs were purchased from R&D systems
(Abingdon, UK) and Insulin ELISA from Mercodia Diagnostics
(Sweden). Diaminobenzidine tetrahydrochloride (DAPI) and
LipidTOX™ Green Neutral Lipid were obtained from Life
Technologies (Warrington, UK). RT2 Proﬁler human adipogenesis
PCR arrays and cDNA synthesis kits were purchased from
SABiosciences-Qiagen, (Hilden, Germany). Other chemicals and re-
agents were purchased from Sigma (Germany) unless otherwise
indicated.
2.2. Cohort
Patient recruitment criteria were previously published [5]. Brieﬂy,
forty consented obese patients (20 females and 20 males, matched for
age and BMI) undergoing weight reduction surgery at Hamad Medical
Corporation (HMC) (Doha, Qatar) were recruited. Protocols were
approved by Institutional Review Boards of HMC and ADLQ (SCH-
ADL-070, SCH-JOINT-111). Blood was collected prior to operation
and 1–5 g OM adipose tissues biopsies were collected during the
surgery. Plasma cholesterol, fasting glucose, Hba1c and liver function
enzymes were measured by COBAS INTEGRA (Roche Diagnostics,
Basil). IL-6, leptin and insulin were determined using commercially
available ELISA. Insulin resistance was computed by homeostatic
model assessment (HOMA-IR) [30] using 30th percentile (HOMA-
IR=2.4) as a threshold point. Accordingly, subjects were dichotomized
into IS (HOMA-IR < 2.4, n=8) and IR (HOMA-IR > 2.4, n=32), includ-
ing 11 subjects with T2DM (5 on metformin only, 5 on metformin and
insulin injection and 1 diet treated).
2.3. Preadipocytes culture and diﬀerentiation
Stromal vascular fraction (SVF) cells were obtained by collagenase
digestion of OM adipose tissues as described previously [31]. Cell
pellets were re-suspended in stromal medium containing DMEM-F12
supplemented with 10% FBS and Penicillin/Streptomycin, then main-
tained at 37 °C with 5% CO2 until conﬂuence. To induce diﬀerentiation,
early passaged SVF-derived preadipocytes (passages 1–3) were grown
at 2×104/cm2 in stromal medium overnight then incubated in diﬀer-
entiation medium (DMEM-F12, 3% FBS, 33 μM biotin, 17 μM D-
pantothenate, 1 μM dexamethasone, 250 μM of methylisobutyl-
xanthine, 0.1 μM human insulin, 5 μM of PPARγ agonist, rosiglitazone)
for 7 days, followed by 12 days in maintenance medium containing
same components as diﬀerentiation medium omitting methylisobutyl-
xanthine and rosiglitazone [32]. Diﬀerentiation potential (adipogenic
capacity) was determined as a percentage of lipidtox positive stained
cells to total number of stained nuclei (DAPI). For experiments
investigating the eﬀect of 4-HNE, metformin, insulin and their various
combinations on diﬀerentiation, cells were grown as above in the
absence or presence of repeated (every 3 days) of 10 µM 4-HNE, 1 mM
metformin, 0.1 μM human insulin or their combinations for the entire
diﬀerentiation and maintenance periods.
2.4. Gene expression studies
RNA was extracted from diﬀerentiated OM adipocytes using Trizol
following manufacturer's instructions. One microgram of RNA was
used to synthetize cDNA and gene expression proﬁling was determined
using RT2 Proﬁler human adipogenesis PCR arrays by assessing mRNA
levels of 84 genes, including ﬁve "housekeeping genes" according to
manufacturer's protocol. The list of genes included Cyclin D1 (CCND1),
Fatty Acid Binding Protein 4 (FABP4), TSC22 Domain Family Member
3 (TSC22D3) and Peroxisome Proliferator-Activated Receptor Gamma
Coactivator 1 Beta (PPARGC1B, also known as PGC1beta). Data were
normalized with the internal housekeeping genes and ΔΔCt was
calculated using ΔCt from IS as the control group according to
manufacturer's protocol.
2.5. Measurement of ROS production
Intracellular ROS levels were assessed using 2′,7′-dichloroﬂuores-
cein-diacetate (DCFH-DA, Fluka) probe as described previously [33].
Brieﬂy, cells were incubated with DCFH-DA (10 µM) in the HBSS for
30 min followed by removal of the probe and treatment with 4-HNE
(10 µM) in stromal medium containing 3% FBS. The ﬂuorescence
intensity (relative ﬂuorescence units, RFU) was measured every hour
for 12 h using TECAN Inﬁnite M200 PRO plate reader equipped with
gas control mode to maintain 37 °C and 5% CO2.
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2.6. 4-HNE staining
Immunohistochemical analysis of adipose tissues biopsies was
performed as previously described [6]. Brieﬂy, formalin-ﬁxed and
paraﬃn-embedded sections made from paraﬃn blocks were stained
with Haematoxylin/Eosin (HE) or with a monoclonal antibody speciﬁc
for the HNE-histidine epitope in HNE-protein (peptide) conjugates.
For the immunohistochemical detection of the HNE-protein adducts
the immunoperoxidase technique was used using EnVision kit (Dako,
Denmark) as described previously [34]. HNE positivity was estimated
using a semi-quantitative method by an experienced pathologist (−0%
positive cells, + < 5% positive cells, ++5–25% positive cells, +++25–
50% positive cells, ++++ > 50% positive cells). The presence of HNE-
protein adducts in connective tissue, inﬂammation and in blood vessels
was deﬁned as negative (-) in the absence of the HNE-protein adducts,
or as low positive (+, ++) or high positive (+++, ++++) in the presence
of the HNE-protein adducts [35].
2.7. Statistical analysis
Comparisons were performed using t-test, Wilcoxon–Mann–
Whitney and 1-way ANOVA in IBM SPSS statistics 21. Signiﬁcance
was deﬁned as P≤0.05. Power calculations indicated that the present
sample size (n=40) had 80% power to detect a minimal diﬀerence of
30% in mean diﬀerentiation capacity of IS versus IR+ type 2 diabetes
mellitus with 35% deviation from mean value (sigma) at a level of
α=0.05.
3. Results
3.1. Insulin resistance-associated impairment of OM adipogenesis
Forty obese and morbidly obese (BMI=43.6 ± 6.7 kg m-2), young
(age=35.6 ± 11.9 years) patients were included in this study. General
characteristics of the cohort were previously published [5] and shown
for the studied group in Supplementary Table S1. Both metformin
monotherapy or metformin and insulin combined therapy exhibited a
comparable glycemic control over T2DM patients as indicated by the
matching Hba1c levels, despite the non-signiﬁcant elevation in FPG
and insulin levels in the combined treatment group. The metformin
and insulin treatment group showed signiﬁcant reduction in systemic
IL-6 levels compared to patients treated with metformin monotherapy
(Table S1).
The adipogenic capacity of SVF-derived preadipocytes was assessed
in all participants. Compared to IS individuals, IR and T2DM patients
exhibited reduced OM adipogenic capacity by 26.3% (p < 0.01)
(Fig. 1A, B). As the obtained data revealed that the adipogenic capacity
was equally reduced in IR and T2DM groups (Fig. 1B), these two
groups were further combined when conducting gene expression
comparison in order to increase the power (Fig. 1C). The reduced
adipogenic capacity of IR & T2DM-derived preadipocytes was asso-
ciated with up-regulation of anti-adipogenic genes CCND1, FABP4 and
TSC22D3 and down-regulation of the pro-adipogenic gene PPARGC1B
(Fig. 1C). Interestingly, preadipocytes expanded from T2DM patients
who were treated with a combination of metformin and insulin showed
greater adipogenic capacity than those treated with metformin mono-
therapy (Fig. 1D), as well as the diet-treated individual (4%). The
reversing of the adipogenic capacity in the combined treatment group
(20.3%), compared to metformin monotherapy group (1.7%) (Fig. 1D),
is still lower than that of the IS group (43.1%, Fig. 1B), perhaps due to
the anti-adipogenic eﬀect of metformin.
3.2. Insulin resistance-associated 4-HNE staining, adipocyte size and
macrophages inﬁltration within OM adipose tissues
A semi-quantitative immunohistochemical analysis of adipose
tissues from randomly selected samples revealed that disease progres-
sion was associated with increased 4-HNE levels in adipocytes
(Fig. 2A), smaller size of the adipocytes (Fig. 2B) and reduced
macrophage inﬁltration (Fig. 2C). However, a lower 4-HNE-immuno-
positivity was detected in OM tissues from metformin and insulin
treated T2DM patients when compared to those treated with metfor-
min monotherapy (Fig. 2D). In the metformin monotherapy group, the
4-HNE immunopositivity was most pronounced in the cellular mem-
branes of the adipocytes (brown color) and occasionally in inﬂamma-
tory cells inﬁltrating the adipose tissue, as indicated by arrows (Fig. 2D
top left image). Furthermore, high 4-HNE immunopositivity was also
detected in the walls of blood vessels and in the perivascular interstitial
connective tissue as indicated by arrows (Fig. 2D top right image). Only
a weak immunopositivity for 4-HNE was seen in the metformin and
insulin group in the membranes of some adipocytes and the blood
vessel walls, while 4-HNE was mostly absent in their OM interstitial
connective tissue (indicated by arrow) as visualized by the blue color of
the hematoxylin contrast (Fig. 2D bottom left image). Furthermore,
lower levels of 4-HNE immunopositivity were usually discontinuously
present in the membranes of the adipocytes and the interstitial blood
vessels in this group (indicated by arrow) (Fig. 2D bottom right image).
3.3. Eﬀect of 4-HNE and metformin treatment in vitro on ROS
production and OM adipogenesis in the presence of insulin
Preadipocytes were treated with metformin, 4-HNE or their
combinations in the presence or absence of insulin (Fig. 3A). Both 4-
HNE and metformin treatments caused signiﬁcant elevation in ROS
production in the absence or presence of insulin (Fig. 3B).
Furthermore, 4-HNE, metformin given alone or combined with 4-
HNE caused reduced adipogenic capacity that was partially rescued by
co-treatment with insulin (Fig. 3A, C). The lipidtox signal in cells
treated with insulin and 4-HNE in the presence of metformin was
lower than when metformin was omitted (Fig. 3A) as quantiﬁed in
Fig. 3C. This is probably due to inhibition of adipogenic capacity in
response to metformin, despite partial rescue due to presence of
insulin. The reduced adipogenic capacity with 4-HNE treatment had
no eﬀect on cell size, whilst metformin treatment decreased the size of
diﬀerentiated cells signiﬁcantly (Fig. 3D). Interestingly, 4-HNE treat-
ment caused a signiﬁcant increase in cell number (p < 0.05), a trend
that was also seen in cells treated with metformin and insulin but did
not reach statistical signiﬁcance (p=0.06) (Fig. 3E).
4. Discussion
The intra-abdominal OM adipose tissue has unique anatomic and
metabolic characteristics compared to adipose tissues at other locations
[36]. Dysfunction of this depot is marked by ectopic fat accumulation
and is often associated with hyperinsulinemia and increased risk of
T2DM [37,38]. Our data report for the ﬁrst time impairment of the
adipogenic capacity of OM preadipocytes taken from obese and morbidly
obese IR individuals (including T2DM patients) compared to their IS
counterparts, with a potential role of 4-HNE accumulation in this
impairment. OM preadipocytes of the IS individuals maintained their
capacity to diﬀerentiate, potentially allowing superﬂuous triacylglycerols
from the sub-cutaneous depot to be stored within the OM depot,
therefore reducing ectopic fat accumulation. This is also supported by
better liver function parameters of IS patients reported previously [5].
Our data also show evidence that T2DM patients who were already
treated with combined metformin and insulin show improved in vitro
adipogenesis compared to those treated with metformin only. This
partial rescue of adipogenesis in the combined therapy group was
associated with less inﬁltration of macrophages and 4-HNE accumula-
tion in their OM adipose tissues. Despite no signiﬁcant diﬀerences in
circulating TAGs between the two groups, the therapeutic relevance of
improved adipogenesis requires veriﬁcation in a larger cohort.
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Insulin resistance-associated impairment of OM adipogenesis was
marked by elevated expression of the anti-adipogenic genes CCND1,
FABP4 and TSC22D3, all shown previously to reduce PPARG-mediated
adipogenesis [39–41], and down-regulation of the pro-adipogenic gene
PPARGC1B that lays downstream of PPARG [42]. Impaired adipogen-
esis was also associated with higher macrophage accumulation and 4-
HNE staining within the adipose tissues (Fig. 2). Indeed both macro-
phages and adipocytes are known to promote inﬂammation and alter
cellular redox homeostasis. Mutual interplay between macrophage
oxidative burst and ROS derived from adipocyte metabolism of excess
nutrients can trigger lipid peroxidation of readily oxidizable adipocyte
lipids yielding formation of 4-HNE [9]. As obesity and T2DM are
associated with dyslipidemia, 4-HNE may be generated from organs or
tissues other than adipose tissues and spread through the blood. This is
consistent with the observations in Fig. 2D where high 4-HNE staining
was primarily detected in the walls of blood vessels and in the
perivascular interstitial tissues. It is likely that 4-HNE is transported
while bound to proteins such as albumin since 4-HNE-protein adducts
are less easily metabolized than free aldehydes that have high aﬃnity to
bind to proteins. In favor of this assumption are also ﬁndings of
increased levels of 4-HNE-protein adducts in the blood of obese men
[15]. Thus, acting as systemic mediator of lipid peroxidation 4-HNE
might modulate cell growth, diﬀerentiation, apoptosis and paly a role
as signaling molecule by its direct action and indirect eﬀect caused by
modiﬁcation of proteins [11]. Moreover, 4-HNE was shown to regulate
adipose tissue function and diﬀerentiation in both mature and in
diﬀerentiating adipocytes [13]. Still, the pathophysiological roles of
oxidative stress, in particular whether 4-HNE is responsible for insulin
resistance, remains to be elucidated [43].
In the current study, T2DM-associated impairment of OM adipo-
genesis was also associated with increased prevalence of small adipo-
cytes, a ﬁnding that was previously attributed to adipocyte hyperplasia
associated with greater degree of insulin resistance and T2DM [44].
Possible causative/mechanistic involvement of 4-HNE in such patho-
physiology of T2DM-associated impairment of OM adipogenesis is
strongly supported by increased levels of 4-HNE observed by immu-
nohistochemical analysis of the OM tissue of these patients (Fig. 2)
together with enhanced proliferation and reduced diﬀerentiation
(adipogenesis) of cultured pre-adipocytes treated with 4-HNE
(Fig. 3). This particular product of lipid peroxidation is well known
to enhance proliferation and regulate metabolic stress-response and
diﬀerentiation as it acts as a growth factor for various types of cells
[45–48].
Furthermore, the ﬁnding of increased ROS production in response
to 4-HNE treatment in vitro indicates that 4-HNE might play crucial
role in the onset of the vicious etio-pathogenic circle of obesity,
Fig. 1. Comparison of adipogenic capacity of OM preadipocytes isolated from insulin sensitive (IS), insulin resistant (IR) and type 2 diabetes mellitus (T2DM) patients treated with
metformin monotherapy or a combination of metformin and insulin. Representative images of diﬀerentiated adipocytes by Arrayscan XTI reader showing ﬂuorescently labelled lipid
droplets (x200) (A). Diﬀerentiation of expanded preadipocytes was assessed by automated scoring of the percentage of lipidtox positive cells (green) to total number of cells (blue)
(adipogenic capacity) in IS (n=8), IR (n=21) and T2DM (n=11) (B). Fold change in gene expression of Cyclin D1 (CCND1), Fatty Acid Binding Protein 4 (FABP4), TSC22 Domain Family
Member 3 (TSC22D3) and PPARG Coactivator 1 Beta (PPARGC1B) in IS (n=5) and IR+T2DM (n=18) using IS diﬀerentiated adipocytes as a control group (C). Adipogenic capacity
(lipidtox positive/total number of cells) of expanded preadipocytes in T2DM treated with metformin (n=5) or a combination of metformin and insulin (n=5) (D). Data are presented as
Mean ± SEM. Diﬀerences between groups were tested by ANOVA followed by independent sample t-test between IS and all IR (IR+T2DM) groups, *P < 0.05.
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inﬂammation, oxidative stress and T2DM, which should be further
studied to better understand metabolic syndrome and develop im-
proved preventive and therapeutic protocols.
Both metformin and insulin are prescribed therapy protocols for
T2DM patients [49]. The synergistic action of insulin with metformin
was shown to improve glycemic control over insulin monotherapy [23].
In this study, we hypothesized that the previously reported anti-
adipogenic eﬀect of metformin could be rescued with co-treatment
with insulin. Indeed, the emerging data suggest rescued adipogenesis
in the combined therapy group which is marked by lower circulating
IL-6 levels and reduced 4-HNE modiﬁed proteins concentrations and
macrophage inﬁltration within the adipose tissues. Diﬀerences in the
adipogenic capacity between the metformin monotherapy and the
combination therapy groups may represent a reﬂection of imprinted
memory on the adipose tissue due to exposure to diﬀerent medications
and their various eﬀects on tissue physiology [5]. The superior
adipogenesis of combined treatment was further conﬁrmed by treating
cells from IR individuals with metformin in the presence of insulin. The
4-HNE treatment reduced adipogenesis, also reported previously
[6,13,21], however this phenotype was rescued in the presence of
insulin. Furthermore, 4-HNE and metformin signiﬁcantly induced
intracellular adipocyte ROS production in vitro while this eﬀect was
also partially blunted by insulin. A similar ﬁnding was previously
reported in 3T3L1 mouse preadipocytes cell line where treatment with
metformin increased ROS production while the combination of met-
formin and insulin did not [50]. The anti-inﬂammatory role of insulin
[51] in the combined treatment group, manifested by lower circulating
IL-6, reduced macrophage inﬁltration within the adipose tissue and the
subsequent lower 4-HNE accumulation and ROS production, may have
contributed to improved adipogenesis in these patients although the
exact mechanism remains to be investigated. Indeed, the anti-adipo-
genic roles of IL-6 and 4-HNE in sub-cutaneous tissues from insulin
resistance and T2DM were recently suggested [5,6] and the emerging
data may suggest a similar role in OM preadipocytes. Fig. 4 represents
proposed action of the combined treatment on OM adipogenesis
through blunting inﬂammation and 4-HNE accumulation, as suggested
by emerging and recently published data [6].
5. Conclusions
Our results demonstrate insulin-resistance associated impairment
of OM adipogenesis and provide a proof of concept that the impaired
preadipocyte diﬀerentiation and altered cellular redox homeostasis in
T2DM patients may be reversible by the synergistic action of insulin
and metformin, potentially allowing for a better storage of excess
triacylglycerols that otherwise would be deposited ectopically. The
involvement of 4-HNE as a potential pathogenic factor and a possible
biomarker of impairment of OM adipogenesis in the IR and T2DM
patients seems consistent with the recognized role of 4-HNE as a
clinical biomarker of diﬀerent diseases [52,53]. Studies are needed to
evaluate these possibilities and explore the underlying pathophysiolo-
gical mechanisms based on inﬂammation and oxidative stress.
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Fig. 2. 4-HNE staining, adipocyte size and macrophage inﬁltration in OM adipose tissue from IS, IR and T2DM patients. 4-HNE immunohistochemical staining (A), adipocyte size (B)
and prevalence of inﬁltrating macrophages (C) within OM adipose tissues (n=17, 3IS, 6IR and 8 T2DM with 4 on metformin and 4 on metformin/insulin) were semi-quantiﬁed by an
experience pathologist without prior knowledge of the experimental groups. Representative images showing 4-HNE staining (indicated by arrows) in OM tissues from T2DM patients
treated with metformin monotherapy (top) or metformin/insulin combined therapy (bottom) (D).
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Fig. 3. The eﬀect of 4-HNE, metformin and insulin treatment on ROS production and OM adipogenesis. Preadipocytes were treated with 10 µM 4-HNE, 1 mM metformin or their
combination in the presence or absence of 0.1 μM human insulin repeatedly for the entire diﬀerentiation and maintenance periods. Representative images showing impaired
adipogenesis (diﬀerentiated adipocytes stained with lipidtox appear in green) in cells treated with 4-HNE and metformin and the partial rescue in the presence of insulin (×100) (A),
together with ROS production (B), adipogenic capacity (C), adipocyte size (D) and cell number (E). Data are presented as Mean ± SEM (n=6). Diﬀerences in paired groups were tested by
paired samples Test (UT: untreated control, Ins: Insulin, Met: Metformin). P < 0.05.
Fig. 4. A scheme representing a proposed mechanism for the anti-adipogenic eﬀect of metformin compared to pro-adipogenic eﬀect of combined metformin and insulin therapy
highlighting the roles of oxidative stress (ROS), macrophages (MF) and inﬂammation.
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